On January 9, a clinical collaboration project on boron neutron capture therapy (BNCT), jointly undertaken by CNNC Haidewei, Fujian Ruisco, and Fujian Medical University Union Hospital, was officially launched in Putian, the hometown of Mazu in Fujian.

According to CNNC Haidewei, the injectable boron[10B] phalan, independently developed by CNNC Haidewei, recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, marking the official entry of the drug into the Phase I clinical trial stage.

Boron neutron capture therapy (BNCT) is a novel radiotherapy method that precisely targets cancer cells. Its principle is based on the specific affinity of boron-10 compounds for cancer cells. After the drug accumulates at the tumor site, neutron beam irradiation triggers a boron neutron capture nuclear reaction, thereby precisely destroying tumor cells while maximally protecting surrounding normal tissues. This represents a highly promising frontier in the field of cancer treatment.

CNNC Haidewei has been deeply involved in the field of radiopharmaceuticals. The newly approved injectable boron [10B] faram will provide core boron drugs for the BNCT treatment system and accelerate the industrialization of BNCT.

https://finance.eastmoney.com/a/202601113615121171.html